SCHEMBL6625545

SCHEMBL6625545

Cc1ncc(COS(C)(=O)=O)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 1/20 0.38
HCAR2 Q8TDS4 1/20 0.35
L3MBTL1 Q9Y468 5/20 0.33
LMNA P02545 2/20 0.33
POLB P06746 1/20 0.33
RAB9A P51151 1/20 0.33
ATM Q13315 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CYP1A2 P05177 2/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
PARG Q86W56 1/20 0.31
GRIN2A Q12879 2/20 0.30
KDM4E B2RXH2 1/20 0.30
USP2 O75604 1/20 0.30
ALDH1A1 P00352 1/20 0.30
MMP9 P14780 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL854995 0.82 CYP1A2 (0.33) L3MBTL1LMNAPOLBRAB9AATM
SCHEMBL1877939 0.82 KMT2A (0.50) L3MBTL1LMNAPOLBRAB9AATM
SCHEMBL9899996 0.78 ALDH1A1 (0.34) POLBMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL16388288 0.77 CNR2 (0.31) SLC6A3L3MBTL1LMNAPOLBRAB9A
SCHEMBL9051664 0.75
SCHEMBL9899927 0.75 MEN1 (0.33) MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL18641577 0.73 NPY5R (0.33)
SCHEMBL13141021 0.73
SCHEMBL15579771 0.73
SCHEMBL19619157 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2024-01-25 US disclosed
US-11814376-B2 Hepatitis b core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2023-11-14 US disclosed
WO-2016162325-A1 SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-A]PYRAZIN-1 (2H)-ONE DERIVATIVES AS KINASE INHIBITORS ASTRAZENECA AB (SE) 2016-10-13 WO disclosed
WO-2016162325-A1 SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-A]PYRAZIN-1 (2H)-ONE DERIVATIVES AS KINASE INHIBITORS ASTRAZENECA AB (SE) 2016-10-13 WO disclosed
EP-0976753-B1 [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES KYOWA HAKKO KOGYO KK (JP) 2004-01-02 EP disclosed
US-6222035-B1 AS ADENOSINE A.SUB.2A RECEPTOR ANTAGONISTS AND ARE USEFUL FOR THERAPY OR OR PROPHYLAXIS OF VARIOUS DISEASES INDUCED BY HYPERACTIVITY OF ADENOSINE A.SUB.2A RECEPTORS SUCH AS PARKINSON'S DISEASE, SENILE DEMENTIA OR DEPRESSION KYOWA HAKKO KOGYO CO., LTD. (JP) 2001-04-24 US disclosed
EP-0976753-A1 [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2000-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS SLC6A3 4731/4885HCAR2 2735/4885L3MBTL1 1920/4885
US-11814376-B2 Hepatitis b core protein modulators HAVCR2, FABP1, MAVS SLC6A3 4731/4885HCAR2 2735/4885L3MBTL1 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.